Hofseth BioCare (BATS-CHIXE:HBCO) - Stock Price, News & Analysis

HBCO Stock Overview

Operates as a consumer and pet health ingredient supplier and incubator in Norway, the United Kingdom, France, Belgium, Europe, Japan, Asia, and the United States.

About the company

HBCO fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Risk Analysis

Earnings have declined by 15.6% per year over past 5 years

Shares are highly illiquid

Has less than 1 year of cash runway

Shareholders have been diluted in the past year

Hofseth BioCare ASA Competitors

Tissue Regenix Group

AIM:TRX

UK£43.5m

Bioventix

AIM:BVXP

UK£190.5m

Arecor Therapeutics

AIM:AREC

UK£28.3m

Avacta Group

AIM:AVCT

UK£197.6m

Price History & Performance

Summary of all time highs, changes and price drops for Hofseth BioCare
Historical stock prices
Current Share Price	NOK 2.70
52 Week High	NOK 2.70
52 Week Low	NOK 2.70
Beta	0.62
11 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	-71.82%
5 Year Change	18.94%
Change since IPO	44.39%

Recent updates

Shareholder Returns

	HBCO	GB Biotechs	GB Market
7D	0%	-0.9%	-0.9%
1Y	n/a	-14.9%	8.6%

Return vs Industry: Insufficient data to determine how HBCO performed against the UK Biotechs industry.

Return vs Market: Insufficient data to determine how HBCO performed against the UK Market.

Price Volatility

Is HBCO's price volatile compared to industry and market?
HBCO volatility
HBCO Average Weekly Movement	n/a
Biotechs Industry Average Movement	8.3%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	9.5%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: HBCO has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine HBCO's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2000	60	Jon Odegard	www.hofsethbiocare.com

Hofseth BioCare ASA operates as a consumer and pet health ingredient supplier in Norway and internationally. Its products include Brilliant salmon oil; OmeGo salmon oil for the maintenance of healthy cholesterol, joint, eye, brain, and cardiovascular function; ProGo, a salmon protein hydrolysate powder for treatment of irondeficiency anaemia, irritable bowel syndrome, and sarcopenia; CalGo, a marine calcium powder produced to support cartilage function, joint health, and bone strength; CollaGo; and PetGo, a non-soluble protein. Hofseth BioCare ASA was incorporated in 2009 and is headquartered in Ålesund, Norway.

Hofseth BioCare ASA Fundamentals Summary

How do Hofseth BioCare's earnings and revenue compare to its market cap?
HBCO fundamental statistics
Market cap	NOK 1.09b
Earnings (TTM)	-NOK 139.56m
Revenue (TTM)	NOK 134.43m

8.1x

P/S Ratio

-7.8x

P/E Ratio

Is HBCO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HBCO income statement (TTM)
Revenue	NOK 134.43m
Cost of Revenue	NOK 121.71m
Gross Profit	NOK 12.72m
Other Expenses	NOK 152.28m
Earnings	-NOK 139.56m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

Aug 25, 2023

Earnings per share (EPS)	-0.35
Gross Margin	9.46%
Net Profit Margin	-103.81%
Debt/Equity Ratio	89.7%

How did HBCO perform over the long term?

See historical performance and comparison

Hofseth BioCare BATS-CHIXE:HBCO Stock Report